06 — Commercial Supply

From development batches to dependable supply.

A product only earns its development cost once it ships consistently. KMS oversees the route from lab-scale trials to commercial supply through a network of manufacturing facilities, keeping the same team across API development, formulation, registration and marketing authorisation so nothing is relearned at the handover.

OutcomePartners receive finished product from a site chosen for their dosage form, market and volume.

Partnership models
5
Partnership models
Products in the 2026 portfolio
43V-20
Products in the 2026 portfolio
Markets served
US · EU · RoW
Markets served

01

How supply works

Each programme is planned around its budget, timeline and market, with resource and regulatory expertise managed centrally. API development, formulation development, regulatory registration and marketing-authorisation support sit alongside supply rather than in separate contracts.

02

Manufacturing networkV-14

Partners draw on a network of manufacturing facilities with different specialised capabilities, so each product is placed where its dosage form and volume are best served.

03

Partnership models

Five ways to engage, from a single dossier to long-term supply.

  • Dossier development
  • Dossier compilation
  • Co-development with profit sharing
  • Technology transfer
  • Commercial supply

04

Markets

Generic and differentiated products for the United States, Europe and rest-of-world markets.

Next capability07 Third-Party Audit & Compliance Assurance

Start a conversation

Where does your programme stand?

Tell us the molecule, the dosage form and the market you are filing in. A programme lead will read it and reply with what we would do next.

Business enquiries: vasanthi@kmshc.com · +91 97898 75194V-23

KMS PharmaChennai